Cancer Genetics — IPO Roadshow (November 2015)
36 slides from Cancer Genetics's IPO roadshow presentation, Nov 2, 2015

Slide 1: The Oncology Diagnostics Partner From Bench to Bedside
The Oncology Diagnostics Partner From Bench to Bedside Investor Presentation NASDAQ: CGIX November 2015

Slide 2: Forward-Looking Statement
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer

Slide 3: Free Writing Prospectus Statement
This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing in our company. We have filed a Registration Statement on Form S-3 with the Securities and Exchange Commission inclu

Slide 4: CGIX - Offering Summary
CGIX - Offering Summary Issuer Cancer Genetics, Inc. Listing NASDAQ Capital Market: CGIX Use of Proceeds General corporate purposes including integration of recent acquisition; sales & marketing to support new product launches; and to fund our contributions to OncoSpire, our JV with Mayo Joint Book-

Slide 5: Large, Global Market Opportunities: Investor Highlights
Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015 Strong & Growing Partnerships with Leading BioPharma CONTRACTS WITH 7 of 10 TOP BIOPHARMA INCREASING REVENUE & PIPELINE(1) WITH BIOPHAR

Slide 6: Our Mission: The Oncology Diagnostics Partner of Choice
Clinical Trials Research Patient Care Our Mission is To be The Oncology Diagnostics Partner of Choice From Bench to Bedside PARTNERING WITH LEADING RESEARCH INSTITUTIONS TO DRIVE INNOVATION AND DEVELOP NEW INSIGHTS DELIVERING CRITICAL GENOMIC INSIGHTS TO MEDICAL PROFESSIONALS TO PERSONALIZE TREATMEN

Slide 7: Uniquely Positioned to Address Macro-Trends in Oncology
Uniquely Positioned to Address Macro-Trends in oncology Increasing Global Need for Improved Diagnosis and Management Global Footprint DEEP, DISEASE-FOCUSED GENOMIC KNOWLEDGE and INSIGHTS PROVEN DISEASE specific & experience CAPABILITIES Growing Awareness & Adoption of Genomic Testing by Clinicians a

Slide 8: Global Oncology Market Forecast & Potential
GLOBAL ONCOLOGY MARKET FORECAST & POTENTIAL GLOBAL SPENDING ($ in Billions) US EU5 JAPAN PHARMERGING ROW Source: IMS Health MIDAS, Dec. 2014; IMS Health Market Prognosis, March 2015. Oncology includes therapeutic treatments as well as supportive care, radiotherapy and immunotherapies $100B ~$135B CA

Slide 9: Key M&A Criteria and Targeted Acquisitions
Key M&A Criteria Targeted Acquisitions 90,000 sq. ft. Global Footprint Response Genetics, Inc. (October 2015) Leading solid tumor testing franchise with content in lung, colorectal, skin and brain cancers as well as FDA-cleared Tissue of Origin Test™ Strong commercial presence in the Western & South

Slide 10: Response Genetics Acquisition Highlights
Combined portfolio covers 8 of the 10 most prevalent cancers Geographic reach Highly experienced sales force focused on the community oncologist & pathologist markets Commercial presence $2-3 MN BioPhaRMA(2) TISSUE Of Origin® is Only FDA-Cleared & Medicare-reimbursed test of its type Extensive & HIG

Slide 11: Anticipated Future Revenues From Biopharma Customers
>$30+M Anticipated Future Revenues From Biopharma Customers Biopharma Revenue and future Growth(1) Approximate expected future revenues under signed contracts with biotechnology & pharma customers for testing & services to support currently planned clinical trials ($ in millions) Strong & growing Re

Slide 12: ICON Partnership
Global CRO industry leader specializing in Phase I through Phase IV clinical trial testing $1.5B in net annual revenue & approximately 11,000 employees ICON has conducted over 950 oncology studies, assessing over 148,000 patients at nearly 27,500 sites worldwide over the past 5 years ICON has expert

Slide 13: Collaborations with Cancer Research Institutions
Collaborations with world-renowned Cancer Research Institutions Disease Target Collaboration Highlights Beth Israel Deaconess Medical Ctr DLBCL (Diffuse Large B-Cell Lymphoma) Biomarker-based outcome prediction using Focus::Lymphoma™ and MatBA®-DLBCL Cleveland Clinic Kidney Cancer Genomic marker val

Slide 14: OncoSpire Genomics Joint Venture
OncoSpire Genomics Joint Venture between Cancer Genetics & Mayo Clinic Joint venture based in Rochester, MN Goal: to develop tests that will become the gold standard in diagnosing and managing patients with selected disease targets Diseases with known clinical dilemmas were selected and informed by

Slide 15: NGS Panel Highlights: Multiple Myeloma
NGS Panel Highlights Multiple Myeloma: Setting the New Standard with a Focused NGS Panel Highly targeted 88 gene panel design Initial design can work on on both major NGS platforms OncoSpire will license to Mayo and CGI for clinical offering 4 papers in the publication process, including at ASH Mult

Slide 16: Unique, Proprietary Portfolio of Genomic Tests & Panels
Tissue of origin® [FDA-Cleared] UroGenRA®-Kidney FHACT® Cervical Focus::Cancer HOTSPOT™ Unique, Proprietary Portfolio of Genomic Tests & Panels Research & Discovery Clinical Development Commercial development Focus::Myeloid™ Focus::Lymphoid™ Focus::CLL™ MatBA® For B-cell Cancers Test In Market 4 Tes

Slide 17: MatBA for Chronic Lymphocytic Leukemia
® Solution MatBA®-CLL/SLL stratifies patients into 3 distinct risk groups using 20 biomarkers: 38% of cases are favorable falling under "watch & wait" approach 8% of Unfavorable cases missed by FISH are detected by MatBA®-CLL/SLL 23% 39% 38% Favorable Intermediate Unfavorable Problem Standard FISH t

Slide 18: UroGenRA-Kidney for Kidney Cancer
GUIDING Management and Appropriate Treatment Selection FOR Kidney cancer Patients with renal masses often undergo unnecessary nephrectomy for accurate diagnosis & experience delay in treatment Over 15% of needle biopsies of renal masses are rendered non-diagnostic Problem UroGenRA®-Kidney assesses 1

Slide 19: FHACT Fits Into Cervical Screening Workflow
FHACT® Fits Directly into Today’s Cervical Screening Workflow 55.0M Pap Smears 3.5M Unclear/ Abnormal 2.0M Procedures 13K Cases of cancer Today, all HPV+ women with abnormal Pap results are referred for colposcopy Several cervical cancer tests are available but the need for less invasive and better

Slide 20: Tissue of Origin Identifies Challenging Tumors
Tissue of Origin® identifies challenging tumors, including metastatic, poorly differentiated & undifferentiated cancers CHANGE IN DIAGNOSIS Working Diagnosis Prior to TOO® Results Working Diagnosis After TOO® Results N = 107 34% of the time Confirm Working diagnosis Identifies a New site(1) 50% of t

Slide 21: Targeted Clinical Trials Drive Revenue Today and Market Share Future
TARGETED CLINICAL TRIALS DRIVE REVENUE TODAY and MARKETSHARE IN THE FUTURE REVENUE TODAY FOR BIOPHARMA SERVICES FUTURE REVENUE IN CLINICAL CARE TODAY future >10 MIGHT TRANSFORM CANCER CARE BASED ON CGI’s estimate of A 15% APPROVAL RATE 2-3 Potential COMPANION DX To Accelerate clinical Growth & profi

Slide 22: Disease-Focused Patent Portfolio
2 US Patents EU India Canada Mature B-Cell Neoplasms 3 US Patents Tissue of Origin 2 US Patents EU Renal Cortical Neoplasms 13 US Patents PCT AU CA China Japan Gene Expression 2 US Patents Canada Chromosomal Analysis Using FISH 2 US Applications Filed PCT Gynecological Cancers & Precancers 3 US Pate

Slide 23: Diversified and Growing Revenue Base
Diversified and Growing Revenue Base 55% 43% 2% Full Year 2014 $10.2M 69% 26% 5% 9 mos 2015* $12.6M Entered into partnership with ICON to offer access to ICON Laboratory Services combined with Cancer Genetics Focus::CLL™ chosen for global clinical trial by leading biotechnology company Biopharma glo

Slide 24: Strong Record of Continuous Growth
Strong Record of Continuous Growth Revenue growth by Year / Category ($ in millions) BIOPHARMA CLINICAL DISCOVERY OTHER 2013-2014 Revenue highlights TOTAL REVENUE GROWTH OF 54% $6.6M TO $10.2M BIOPHARMA REVENUE GROWTH OF 112% $2.7M TO $5.6M CLINICAL REVENUE GROWTH 0F 21% $3.7M TO $4.4M $4.3 $6.6 $10

Slide 25: Strong Record of Continuous Growth: 9 Month Revenue
Strong Record of Continuous Growth first 9 months 9 mos Revenue 2014-2015 / Category ($ in millions) BIOPHARMA CLINICAL DISCOVERY 9 mos Revenue 2014-2015 highlights TOTAL REVENUE GROWTH OF 104% $6.2M TO $12.6M BIOPHARMA REVENUE GROWTH OF 207% $2.8M TO $8.6M $6.2 $12.6 * 9 mos 2015 based on prelimina

Slide 26: Pro Forma Revenues
PRO FORMA REVENUES * The pro forma revenue numbers above may not be indicative of the consolidated results in the future. Acquisition completed October 2015. 2013 2014 Thru 9/30/2015* CANCER GENETICS RESPONSE GENETICS PRO FORMA ($ in millions) +$32M PRO FORMA ANNUAL REVENUE RUN RATE* ~$4.5M ADDITION

Slide 27: Cancer Genetics Standalone Summary Statement of Operations
Cancer genetics Standalone summary Statement of Operations Summarized income statements (dollars in thousands) Summarized Balance sheet (dollars in thousands) 2014 9 mos 2015 9 mos* Revenue $6,164 $12,556 Gross Profit 805 3,213 Gross Margin (%) 13% 26% Research & Development 3,093 4,335 Sales & Mark

Slide 28: Historical Clinical Reimbursement Mix & Payer Coverage
CGI Payment history – 9 months 2015 (clinical revenues only) 33% 29% Regional And National Payers Medicare Commercial Payers 38% Direct bill Covered Lives Represented by agreements with national integrated networks America’s Choice Provider Blue Cross Blue Shield of Alabama Blue Cross Blue Shield of

Slide 29: Capital Structure
Capital Structure Fully-Dilutive Shares Outstanding as of 10/28/2015 % . Company Stock, Issued & Outstanding 10,651,924 77.3% Equity Awards – Stock Options1 2,004,853 14.6% Warrants2 1,116,940 8.1% Fully-Diluted Shares Outstanding 13,773,717 100% 1 Weighted-average exercise price of $10.52. 2 Weight

Slide 30: Upcoming Presentations
Upcoming Presentations AMP Annual Meeting, November 5-7, 2015 A Multi-Platform Approach for the Detection of Mutations in 54 Genes with Relevance to Myeloid Neoplasms in a Clinical Laboratory Setting Systematic Analysis of Common Copy Number Variations in Diffuse Large B-cell Lymphomas International

Slide 31: Significant Ongoing Milestones Expected in Coming Quarters
SIGNIFICANT ONGOING Milestones Expected in Coming Quarters Major partnerships and contracts with leading oncology therapeutic companies Contracts in immuno-oncology programs with Top 10 pharma and biotechs Announcements of milestones from ICON program and strategic alliance Leveraging capabilities f

Slide 32: Experienced Leadership Team
Experienced leadership team Panna Sharma Chief Executive Officer & President, Board Member Edward J. Sitar, CPA Chief Financial Officer & Treasurer Rita Shaknovich, MD, PhD Group Medical Director & VP, Hematopathology Services Mandar Kulkarni, PhD Chief Technology Officer, India Jane Houldsworth, Ph

Slide 33: Board of Directors
BOARD OF DIRECTORS Panna Sharma CEO & president of Cancer Genetics General Manager of OncoSpire Genomics Previously managing partner/founder of TSG Partners 70+ buy & sell-side transactions (healthcare companies) Raju S.K. Chaganti, PhD Founded CGI & served as Chairman until 2014 Internat’ly recogni

Slide 34: Large, Global Market Opportunities: Investor Highlights
Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015 Strong & Growing Partnerships with Leading BioPharma CONTRACTS WITH 7 of 10 TOP BIOPHARMA INCREASING REVENUE & PIPELINE(1) WITH BIOPHAR

Slide 35: The Oncology Diagnostics Partner From Bench to Bedside
The Oncology Diagnostics Partner From Bench to Bedside CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 Fax: +1 919-465-0554 RALEIGH, NC LOS AN

Slide 36: Tissue of Origin Competitor Comparison
Tissue of origin® competitor comparison CRITERIA Tissue of Origin® CancerTYPE ID™ Cancer Origin Test™ EXTERNAL REVIEW FDA CLEARED Yes No No MEDICARE COVERED Yes Yes Yes PEER-REVIEWED PUBLICATIONS 23 21 6 VALIDATION STUDY NUMBER OF GENES MEASURED 2,000 92 64 Accuracy (measured as Positive Percent Agr
Source: SEC EDGAR · FWP filed Nov 2, 2015
More decks from Cancer Genetics Inc
Vyant Bio — Q1 2022 Earnings Presentation14 slides · May 16, 2022
Merger or Acquisition (January 2021)15 slides · Jan 8, 2021
Merger or Acquisition (September 2020)22 slides · Sep 15, 2020
Q2 2018 Earnings Presentation10 slides · Aug 14, 2018
Q1 2018 Earnings Presentation11 slides · May 15, 2018
FY2017 Earnings Presentation12 slides · Apr 2, 2018